Judith Olde Heuvel1,2, Berlinda J de Wit-van der Veen3, Henk G van der Poel4, Pim J van Leeuwen4, Elise M Bekers5, Maarten R Grootendorst6, Kunal N Vyas6, Cornelis H Slump2, Marcel P M Stokkel1. 1. Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands. 2. Technical Medical Centre, University of Twente, Enschede, The Netherlands. 3. Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands; l.vd.veen@nki.nl. 4. Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 5. Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; and. 6. Lightpoint Medical Ltd., Chesham, United Kingdom.
Abstract
Cerenkov luminescence imaging (CLI) is a novel imaging technology that might have the ability to assess surgical margins intraoperatively during prostatectomy using 68Ga-prostate-specific membrane antigen (68Ga-PSMA-11). This study evaluated the accuracy of CLI compared with histopathology and, as an exploratory objective, investigated the characteristics of the identified chemiluminescence signal. Methods: After intravenous injection of a mean 68Ga-PSMA-11 activity of 69 MBq intraoperatively, all excised specimens were imaged with CLI. Areas of increased signal were marked for histopathologic comparison and scored for the likelihood of being a positive surgical margin (PSM) using a 5-point Likert scale. In addition, the chemiluminescence signal was investigated in 3 radioactive and 3 nonradioactive specimens using CLI. Results: In 15 patients, the agreement between CLI and histopathology was 60%; this improved to 83% when including close surgical margins (≤1 mm). In 6 hot spots, CLI correctly identified PSMs on histopathology, located at the apex and mid prostate. In all 15 patients, an increased signal at the prostate base was observed, without the presence of the primary tumor in this area in 8 patients. This chemiluminescence signal was also observed in nonradioactive prostate specimens, with a half-life of 48 ± 11 min. The chemiluminescence hampered the visual interpretation of 4 PSMs at the base. Conclusion: CLI was able to correctly identify margin status, including close margins, in 83% of the cases. The presence of a diathermy-induced chemiluminescent signal hampered image interpretation, especially at the base of the prostate. In the current form, CLI is most applicable to detect PSMs and close margins in the apex and mid prostate.
Cerenkov luminescence imaging (CLI) is a novel imaging technology that might have the ability to assess surgical margins intraoperatively during prostatectomy using 68Ga-prostate-specific membrane antigen (68Ga-PSMA-11). This study evaluated the accuracy of CLI compared with histopathology and, as an exploratory objective, investigated the characteristics of the identified chemiluminescence signal. Methods: After intravenous injection of a mean 68Ga-PSMA-11 activity of 69 MBq intraoperatively, all excised specimens were imaged with CLI. Areas of increased signal were marked for histopathologic comparison and scored for the likelihood of being a positive surgical margin (PSM) using a 5-point Likert scale. In addition, the chemiluminescence signal was investigated in 3 radioactive and 3 nonradioactive specimens using CLI. Results: In 15 patients, the agreement between CLI and histopathology was 60%; this improved to 83% when including close surgical margins (≤1 mm). In 6 hot spots, CLI correctly identified PSMs on histopathology, located at the apex and mid prostate. In all 15 patients, an increased signal at the prostate base was observed, without the presence of the primary tumor in this area in 8 patients. This chemiluminescence signal was also observed in nonradioactive prostate specimens, with a half-life of 48 ± 11 min. The chemiluminescence hampered the visual interpretation of 4 PSMs at the base. Conclusion: CLI was able to correctly identify margin status, including close margins, in 83% of the cases. The presence of a diathermy-induced chemiluminescent signal hampered image interpretation, especially at the base of the prostate. In the current form, CLI is most applicable to detect PSMs and close margins in the apex and mid prostate.
Authors: Hemamali Samaratunga; Rodolfo Montironi; Lawrence True; Jonathan I Epstein; David F Griffiths; Peter A Humphrey; Theo van der Kwast; Thomas M Wheeler; John R Srigley; Brett Delahunt; Lars Egevad Journal: Mod Pathol Date: 2010-09-10 Impact factor: 7.842
Authors: Maarten R Grootendorst; Massimiliano Cariati; Sarah E Pinder; Ashutosh Kothari; Michael Douek; Tibor Kovacs; Hisham Hamed; Amit Pawa; Fiona Nimmo; Julie Owen; Vernie Ramalingam; Sweta Sethi; Sanjay Mistry; Kunal Vyas; David S Tuch; Alan Britten; Mieke Van Hemelrijck; Gary J Cook; Chris Sibley-Allen; Sarah Allen; Arnie Purushotham Journal: J Nucl Med Date: 2016-12-08 Impact factor: 10.057
Authors: Jason P Izard; Lawrence D True; Philip May; William J Ellis; Paul H Lange; Bruce Dalkin; Daniel W Lin; Rodney A Schmidt; Jonathan L Wright Journal: Am J Surg Pathol Date: 2014-03 Impact factor: 6.394
Authors: Ofer Yossepowitch; Alberto Briganti; James A Eastham; Jonathan Epstein; Markus Graefen; Rodolfo Montironi; Karim Touijer Journal: Eur Urol Date: 2013-08-03 Impact factor: 20.096
Authors: Margaretha A van der Slot; Michael A den Bakker; Sjoerd Klaver; Mike Kliffen; Martijn B Busstra; John B W Rietbergen; Melanie Gan; Karen E Hamoen; Leo M Budel; Natascha N T Goemaere; Chris H Bangma; Jozien Helleman; Monique J Roobol; Geert J L H van Leenders Journal: Histopathology Date: 2020-09-03 Impact factor: 5.087
Authors: Judith Olde Heuvel; Berlind J de Wit-van der Veen; Daphne M V Huizing; Henk G van der Poel; Pim J van Leeuwen; Patrick A Bhairosing; Marcel P M Stokkel; Cornelis H Slump Journal: Eur Urol Focus Date: 2020-02-20
Authors: Judith Olde Heuvel; Berlinda J de Wit-van der Veen; Henk G van der Poel; Elise M Bekers; Maarten R Grootendorst; Kunal N Vyas; Cornelis H Slump; Marcel P M Stokkel Journal: Eur J Nucl Med Mol Imaging Date: 2020-04-02 Impact factor: 9.236